New tissue graft shows promise for breast reconstruction after mastectomy
NCT ID NCT06853964
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study evaluates the safety and effectiveness of AlloMend®, a human tissue graft, in women undergoing breast reconstruction after mastectomy. Researchers will review medical records of 100 patients to see how well the graft works and track any complications over 12 months. The goal is to understand if this approach leads to better surgical outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AlloMend® Acellular Dermal Matrix (a human tissue graft used to support breast reconstruction)
- What this could lead to
- If successful, this could confirm that AlloMend® is a safe and effective option for breast reconstruction after mastectomy, potentially improving surgical outcomes and reducing complications.
- What could go wrong
- This is a small, retrospective study (100 patients) that looks back at past records, so it cannot prove cause and effect. Results may not apply to all patients, and complications like infection or graft failure are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRE-PECTORAL BREAST RECONSTRUCTION FOLLOWING MASTECTOMY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Janiga MDs Plastic Surgery and Cosmetic Center
Reno, Nevada, 89521, United States